Table 2.
The correlation of DAXX expression with clinicopathological prognostic factors (N=60)
| Variable | Total (%) | DAXX expression | p-value | ||
|---|---|---|---|---|---|
| Negative (%) | Positive (%) | ||||
| 11%–50% of tumor cells | >50% pf tumor cells | ||||
| DAXX expression | 60 | 17 (28.3) | 19 (31.7) | 24 (40.0) | |
| Mean age (yr) | 62.45 | 62.65±6.736 | 60.53±10.33 | 63.83±7.118 | 0.718 |
| Gender | 0.162 | ||||
| Male | 54 (90.0) | 14 (23.3) | 17 (28.3) | 23 (38.3) | |
| Female | 6 (10.0) | 3 (5.0) | 2 (3.3) | 1 (1.7) | |
| T stage | 0.128 | ||||
| T1a | 9 (15.5) | 5 (8.3) | 2 (3.3) | 2 (3.3) | |
| T1b | 6 (10.0) | 2 (3.3) | 1 (1.7) | 3 (5.0) | |
| T2 | 16 (26.7) | 4 (6.7) | 6 (10.0) | 6 (10.0) | |
| T3 | 29 (48.3) | 6 (10.0) | 10 (16.7) | 13 (21.7) | |
| T4 | 0 | 0 | 0 | 0 | |
| pN stage | 0.007 | ||||
| N0 | 30 (50.0) | 12 (20.0) | 10 (16.7) | 8 (13.3) | |
| N1 | 25 (41.7) | 5 (8.3) | 8 (13.3) | 12 (20.0) | |
| N2 | 5 (8.3) | 0 | 1 (1.7) | 4 (6.7) | |
| AJCC staging | |||||
| IA | 11 (18.3) | 6 (10.0) | 2 (3.3) | 3 (5.0) | 0.001 |
| IB | 3 (5.0) | 1 (1.7) | 1 (1.7) | 1 (1.7) | |
| IIA | 12 (20.0) | 5 (8.3) | 6 (10.0) | 1 (1.7) | |
| IIB | 7 (11.7) | 3 (5.0) | 1 (1.7) | 3 (5.0) | |
| III | 10 (16.7) | 1 (1.7) | 4 (6.7) | 5 (8.3) | |
| IV | 17 (28.3) | 1 (1.7) | 5 (8.3) | 11 (18.3) | |
Values are presented as number (%) or mean±standard deviation.
DAXX, death domain-associated protein; AJCC, American Joint Committee on Cancer.